Cardiovascular Drugs Practice Questions

Q: Which vitamin is used in the treatment of hyperlipoproteinemia?

Niacin/Nicotinic acid. Explanation: **Correct Option: C (Niacin/Nicotinic acid)** Niacin (Vitamin B3) is a water-soluble vitamin that, when used in pharmacological doses (grams per day), acts as a potent lipid-lowering agent [1]. It inhibits the enzyme **hormone-sensitive lipase** in adipose tissue, reducing the breakdown of triglycerides into free fatty acids (FFAs). Since FFAs are the primary substrate for hepatic VLDL synthesis, Niacin effectively lowers VLDL and LDL levels [2]. Most importantly, it is the **most effective drug for increasing HDL levels** (by decreasing its fractional clearance). **Incorrect Options:** * **Vitamin B1 (Thiamine):** Primarily used to treat Beriberi and Wernicke-Korsakoff syndrome; it has no role in lipid metabolism. * **Vitamin B6 (Pyridoxine):** Used to prevent peripheral neuropathy (e.g., with Isoniazid therapy) and in sideroblastic anemia; it does not affect lipoprotein levels. * **Vitamin B12 (Cyanocobalamin):** Essential for DNA synthesis and neurological function; its deficiency leads to megaloblastic anemia and subacute combined degeneration of the spinal cord. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common side effect is **cutaneous flushing** (mediated by Prostaglandin D2/E2). This can be prevented by pre-treating with **Aspirin**. * **Metabolic Concerns:** Niacin can cause **hyperuricemia** (precipitating gout) and **hyperglycemia** (use with caution in diabetics) [1]. It may also cause acanthosis nigricans. * **Drug of Choice:** While statins are first-line for LDL reduction, Niacin is historically significant for patients with low HDL or elevated Lipoprotein(a) [2].

Q: Which lipid-lowering drug significantly reduces lipoprotein–a levels?

Nicotinic acid. **Explanation:** **Correct Answer: D. Nicotinic acid (Niacin)** Nicotinic acid is the most effective conventional lipid-lowering agent for reducing **Lipoprotein(a) [Lp(a)]** levels, typically achieving a reduction of 20–30%. It works by inhibiting the hepatic synthesis of apolipoprotein(a), the key component of Lp(a). While newer agents like PCSK9 inhibitors also reduce Lp(a), Nicotinic acid remains the classic pharmacological answer for this specific effect in medical examinations. **Analysis of Incorrect Options:** * **A & B (Fibrates - Fenofibrate/Gemfibrozil):** These are PPAR-α agonists primarily used to lower triglycerides and increase HDL. They have no significant or consistent effect on Lp(a) levels. * **C (Statins - Rosuvastatin):** Statins are the first-line treatment for lowering LDL-C by inhibiting HMG-CoA reductase. Interestingly, statins do not lower Lp(a) and, in some patients, may even cause a slight paradoxical increase in its levels. **High-Yield Clinical Pearls for NEET-PG:** * **Lp(a) Significance:** It is an independent risk factor for atherosclerosis and aortic stenosis. It is structurally similar to plasminogen and can interfere with fibrinolysis. * **Niacin’s "Best" Profile:** It is the most potent drug for **increasing HDL** levels. * **Side Effects:** The most common side effect is **cutaneous flushing** (mediated by Prostaglandin $D_2$), which can be prevented by taking Aspirin 30 minutes prior. It can also cause hyperuricemia (gout) and hyperglycemia. * **Newer Agents:** PCSK9 inhibitors (e.g., Evolocumab) also significantly reduce Lp(a), but Niacin is the traditional drug of choice for this question.

Q: Which of the following drugs is not used for the management of acute pulmonary edema?

Phenylephrine. ### Explanation The primary goal in managing acute pulmonary edema (APE) is to reduce pulmonary venous pressure by improving cardiac output and decreasing preload and afterload. **Why Phenylephrine is the Correct Answer:** Phenylephrine is a **pure $\alpha_1$-adrenergic agonist**. It causes potent systemic vasoconstriction, which significantly increases systemic vascular resistance (SVR) and afterload. In a failing heart (the typical cause of APE), an increase in afterload further reduces stroke volume and increases back-pressure into the pulmonary circulation, potentially worsening the edema. Therefore, it is generally **contraindicated** in APE. **Analysis of Incorrect Options:** * **Dobutamine:** A potent $\beta_1$ agonist with some $\beta_2$ activity. It is an "inodilator" that increases cardiac contractility and reduces afterload, making it a first-line agent for cardiogenic pulmonary edema with low cardiac output. * **Dopamine:** At medium doses (5–10 µg/kg/min), it acts on $\beta_1$ receptors to increase contractility. It is used when APE is accompanied by hypotension. * **Norepinephrine:** While it has $\alpha_1$ effects, its strong $\beta_1$ inotropic effect helps maintain cardiac output in cases of APE associated with severe cardiogenic shock (SBP < 70 mmHg) where maintaining coronary perfusion pressure is critical. **NEET-PG High-Yield Pearls:** * **Mnemonic for APE Management:** **LMNOP** (L-Loop diuretics/Lasix, M-Morphine, N-Nitrates, O-Oxygen, P-Position/Positive pressure ventilation). * **Inotropes vs. Vasopressors:** In APE, we prefer drugs that increase contractility without excessively increasing afterload. * **Phenylephrine Use Case:** It is primarily used for "warm shock" (sepsis) or anesthesia-induced hypotension where the heart is healthy but peripheral resistance is low.

Q: What is the mechanism of action of trimetazidine?

Inhibiting mitochondrial LC3-KAT. **Explanation:** **Mechanism of Action (Correct Answer: D)** Trimetazidine is a metabolic modulator used in the management of chronic stable angina. Its primary mechanism involves the **selective inhibition of long-chain 3-ketoacyl-CoA thiolase (LC3-KAT)**, a key enzyme in the mitochondrial fatty acid $\beta$-oxidation pathway. By inhibiting fatty acid oxidation, the drug shifts myocardial metabolism toward **glucose oxidation**. Since glucose oxidation requires less oxygen per mole of ATP produced compared to fatty acid oxidation, the heart becomes more oxygen-efficient, protecting cardiomyocytes from ischemic injury without affecting heart rate or blood pressure. **Analysis of Incorrect Options:** * **A. Fatty acid synthase inhibitor:** This enzyme is involved in the *synthesis* of fatty acids in the cytosol, not their mitochondrial oxidation for energy. * **B. Na channel inhibitor:** This describes Class I antiarrhythmics (like Lidocaine) or Ranolazine (which inhibits the *late* inward sodium current). * **C. K channel opener:** This is the mechanism of drugs like **Nicorandil** (which also has nitrate-like properties) or Minoxidil. **NEET-PG High-Yield Pearls:** * **Classification:** Trimetazidine is classified as a "pFOX inhibitor" (Partial Fatty Acid Oxidation inhibitor). * **Hemodynamic Neutrality:** Unlike nitrates or beta-blockers, it does not alter heart rate, blood pressure, or coronary blood flow, making it an excellent add-on therapy. * **Side Effects:** A high-yield point for exams is that Trimetazidine can induce **Parkinsonian symptoms** (tremors, rigidity) and gait disturbances, especially in the elderly, due to its ability to cross the blood-brain barrier. It is contraindicated in Parkinson’s disease.

Q: All of the following statements about beta blockers are true EXCEPT?

Atenolol is safe in renal failure.. ### Explanation **1. Why Option D is the Correct Answer (The False Statement):** Atenolol is a **highly hydrophilic (water-soluble)** beta-blocker. Unlike lipophilic drugs (like Propranolol) which are metabolized by the liver, Atenolol is primarily excreted **unchanged by the kidneys**. Therefore, in patients with renal failure, the drug accumulates, leading to toxicity (profound bradycardia and hypotension). It requires significant dose adjustment or avoidance in renal impairment. **2. Analysis of Other Options:** * **Option A (True):** Nebivolol is a third-generation, **highly cardioselective** $\beta_1$ blocker. It also possesses unique vasodilatory properties mediated by the release of Nitric Oxide (NO) from the endothelium. * **Option B (True):** Cardioselective beta-blockers (e.g., Metoprolol, Atenolol, Bisoprolol) preferentially block $\beta_1$ receptors. While they are "relatively" safe in mild-to-moderate asthma because they avoid $\beta_2$ blockade (which causes bronchospasm), they should still be used with extreme caution as selectivity is lost at higher doses. * **Option C (True):** In **acute** decompensated heart failure, beta-blockers are contraindicated because their negative inotropic effect can further worsen cardiac output. However, they are a cornerstone of therapy in **chronic** stable heart failure (specifically Metoprolol succinate, Bisoprolol, and Carvedilol). **3. NEET-PG High-Yield Pearls:** * **Lipophilic Beta Blockers:** Propranolol, Metoprolol. (Undergo extensive first-pass metabolism; cross the Blood-Brain Barrier). * **Hydrophilic Beta Blockers:** Atenolol, Sotalol, Nadolol. (Excreted by kidneys; longer half-lives). * **Shortest Acting:** Esmolol (metabolized by RBC esterases; $t_{1/2} \approx 9$ mins). * **Longest Acting:** Nadolol. * **Beta Blockers with ISA (Intrinsic Sympathomimetic Activity):** Pindolol, Acebutolol (preferred in patients with resting bradycardia).

Q: Which drug possesses beta-adrenergic blocking, antioxidant, calcium channel blocking, and alpha-1 antagonist activities?

Carvedilol. **Explanation:** **Carvedilol** is a unique, non-selective third-generation beta-blocker. Its multifaceted pharmacological profile makes it the correct answer: * **Beta-Blocking:** It blocks both $\beta_1$ and $\beta_2$ receptors. * **Alpha-1 Antagonism:** It provides peripheral vasodilation by blocking $\alpha_1$ receptors, which reduces afterload. * **Antioxidant Activity:** It possesses carbazole rings that scavenge free radicals, preventing lipid peroxidation and protecting the myocardium from oxidative stress. * **Calcium Channel Blocking:** At higher concentrations, it exhibits membrane-stabilizing activity and weak L-type calcium channel blockade. **Analysis of Incorrect Options:** * **A. Esmolol:** An ultra-short-acting, cardioselective ($\beta_1$) blocker. It lacks alpha-blocking or antioxidant properties and is primarily used for acute arrhythmia or intraoperative hypertension. * **C. Nebivolol:** A highly selective $\beta_1$ blocker. While it causes vasodilation, it does so via **Nitric Oxide (NO) release**, not $\alpha_1$ blockade. It does not have significant calcium channel blocking activity. * **D. Levobunolol:** A non-selective beta-blocker used topically in the eye for glaucoma. It lacks the ancillary vasodilator and antioxidant properties of carvedilol. **High-Yield Clinical Pearls for NEET-PG:** * **Heart Failure:** Carvedilol is a "gold standard" beta-blocker (along with Metoprolol succinate and Bisoprolol) proven to reduce mortality in Chronic Heart Failure (CHF). * **Lipid Neutrality:** Unlike first-generation beta-blockers, carvedilol does not adversely affect lipid profiles or insulin sensitivity due to its $\alpha_1$ blocking effect. * **Metabolism:** It is highly lipophilic and undergoes extensive hepatic metabolism.

Question 1

Which vitamin is used in the treatment of hyperlipoproteinemia?

Accepted Answer

Niacin/Nicotinic acid

Answer

Vitamin B1

Answer

Vitamin B6

Answer

Vitamin B12

Question 2

A 65-year-old male had a myocardial infarction one year ago. The same patient now presents with hypertension. Which of the following drugs is best suited for this patient?

Accepted Answer

Lisinopril

Answer

Clonidine

Answer

Thiazide

Answer

Propranolol

Question 3

Which lipid-lowering drug significantly reduces lipoprotein–a levels?

Accepted Answer

Nicotinic acid

Answer

Fenofibrate

Answer

Gemfibrosil

Answer

Rosuvastatin

Question 4

Which of the following drugs is not used for the management of acute pulmonary edema?

Accepted Answer

Phenylephrine

Answer

Norepinephrine

Answer

Dopamine

Answer

Dobutamine

Question 5

It is essential to give a beta-blocker or Digoxin to increase the refractoriness of the AV node (AVN) prior to administration of which of the following for the treatment of atrial fibrillation?

Accepted Answer

All of the above

Answer

Quinidine

Answer

Flecainide

Answer

Moricizine

Question 6

What is the mechanism of action of trimetazidine?

Accepted Answer

Inhibiting mitochondrial LC3-KAT

Answer

Fatty acid synthase inhibitor

Answer

Na channel inhibitor

Answer

K channel opener

Question 7

Which of the following PDE-5 inhibitors has no significant interaction with high-fat meal intake?

Accepted Answer

Tadalafil

Answer

Sildenafil

Answer

Vardenafil

Answer

All of the above

Question 8

All of the following statements about beta blockers are true EXCEPT?

Accepted Answer

Atenolol is safe in renal failure.

Answer

Nebivolol is a cardioselective beta blocker.

Answer

Cardioselective beta blockers are relatively safe in asthma.

Answer

Beta blockers are contraindicated in acute congestive heart failure.

Question 9

Which drug causes a decrease in the late sodium current?

Accepted Answer

Ranolazine

Answer

Nicorandil

Answer

Trimetazidine

Answer

Molsidomine

Question 10

Which drug possesses beta-adrenergic blocking, antioxidant, calcium channel blocking, and alpha-1 antagonist activities?

Accepted Answer

Carvedilol

Answer

Esmolol

Answer

Nebivolol

Answer

Levobunolol

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?